Ignite Creation Date:
2024-05-05 @ 12:02 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00216346
Status:
COMPLETED
Last Update Posted:
2014-10-03
First Post:
2005-09-13
Brief Title:
Safety and Efficacy Study of Paromomycin to Treat Visceral Leishmaniasis
Sponsor:
PATH
Organization:
PATH
Study Overview
Official Title:
A Phase 3 Multicenter Randomized Controlled Clinical Trial to Assess the Safety and Efficacy of Injectable Paromomycin in Patients With Visceral Leishmaniasis
Status:
COMPLETED
Status Verified Date:
2014-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Symptomatic Visceral LeishmaniasisVLis fatal Due to the increasing resistance to standard therapy with antimonials there is a need for new safe efficacious low-cost therapies for the treatment of VL Paromomycin is an off-patent aminoglycoside antibiotic with anti-leishmaniasis activity This study will test the safety and efficacy of paromomycin in the treatment of patients with VL in India
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None